Bizarre Patents
Crispy Chip Sandwich and Process of Producing a Sandwich Product
A food product comprising a multilayer cookie or snack having outer layers formed from a crispy type edible food product such as a potato chip or corn chip, etc. with an intermediate marshmallow layer being in contact with the inner surface of each crispy chip and one or more filler substances.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7425332 | Treatment of autoimmune conditions with Copolymer 1 and related Copolymers The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at l... | 09/16/2008 |
| 7423011 | Therapeutic chemokine receptor antagonists The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T... | 09/09/2008 |
| 7357925 | Method for treating disorders and diseases treatable with human fibroblast interferon PEG-IFN-β conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-β, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors... | 04/15/2008 |
| 7285531 | Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor The invention involves prophylaxis or treatment of nervous system pathological conditions. This is accomplished by administering secretable glial growth factors, such as the molecule referred to as GGF-2. ... | 10/23/2007 |
| 7256184 | Treatment of aging disorders in humans A method for the treatment and prophylaxis of conditions of aging in humans, such conditions of aging associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes. Such conditions include chronic neurodegenerative conditions including... | 08/14/2007 |
| 7235590 | Use of treosulfan and derivatives thereof for treating multiple sclerosis The invention relates to the use of treosulfan and/or derivatives thereof for producing a pharmaceutical composition used in the treatment of multiple sclerosis. ... | 06/26/2007 |
| 7230015 | Method of treating of demyelinating diseases or conditions N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord... | 06/12/2007 |
| 7179821 | Method of treating of demyelinating diseases or conditions N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord... | 02/20/2007 |
| 7141558 | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allow... | 11/28/2006 |
| 7138115 | Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suit... | 11/21/2006 |
| 7074827 | Method for treating ocular hypertension and glaucoma Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a su... | 07/11/2006 |
| 7074403 | Immunotherapy of autoimmune disorders using antibodies which target B-cells Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produ... | 07/11/2006 |
| 7011854 | Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke... | 03/14/2006 |
| 6984625 | Methods and compositions for modulating autoimmunity Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an OX-2 protein or a nucleic acid encoding an OX-2 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune ... | 01/10/2006 |
| 6972280 | Glial mitogenic factors, their preparation and use Disclosed are methods for inducing myelination of neural cells by glial cells, The methods involve contacting glial cells with polypeptides comprising epidermal growth factor-like domains encoded by the GGF/p185 erb B2 ligand gene provided as a feature of the invent... | 12/06/2005 |
| 6967210 | Method of treating of demyelinating diseases or conditions N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord... | 11/22/2005 |
| 6939539 | Copolymer-1 improvements in compositions of copolymers The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons. ... | 09/06/2005 |
| 6933276 | Methods of treating peripheral neuropathies using neurotrophin-3 The present invention relates to neurotrophin-3 (NT-3), a newly discovered member of the BDNF gene family. It is based, in part, on the identification of regions of nucleic acid sequence homology shared by BDNF and NGF (U.S. patent application Ser. No. 07/400,591, f... | 08/23/2005 |
| 6797722 | Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases The present invention discloses a method for treating a subject affected by an autoimmune disease, in particular multiple sclerosis, lupus erythematosus systemicus and reumatoid arthritis, comprising administering to said subject an effective amount of 3-(2-ethylphe... | 09/28/2004 |
| 6767564 | Use of bowman birk inhibitor for the treatment of multiple sclerosis and other autoimmune diseases The present invention provides a non-toxic therapy and a novel use for Bowman Birk Inhibitor (BBI), as administered in Bowman Birk Inhibitor Concentrate (BBIC), for the treatment of autoimmune diseases in a patient, wherein the disease is characterized by chronic in... | 07/27/2004 |
| 6710033 | Methods and treatment of multiple sclerosis The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or ... | 03/23/2004 |
| 6699495 | Methods for treating multiple sclerosis employing desmethylselegiline Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions re... | 03/02/2004 |
| 6669941 | Soluble lymphotoxin-ଲ receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease This invention relates to compositions and methods comprising "lymphotoxin-ଲ receptor blocking agents", which block lymphotoxin-ଲ receptor signalling. Lymphotoxin-ଲ receptor blocking agents are useful for treating lymphocyte-mediated imm... | 12/30/2003 |
| 6642258 | Use of central cannabinoid receptor antagonist for preparing medicines The invention relates to the use of a central cannabinoid receptor antagonist for the preparation of medicinal products that are useful in treating and preventing neuroinflammatory pathologies.... | 11/04/2003 |
| 6613756 | Use of tetracycline derivatives in treating multiple sclerosis A method of treating multiple sclerosis is disclosed. In one embodiment, the method comprises the step of treating a multiple sclerosis patient with a tetracycline derivative, wherein the multiple sclerosis symptoms of the patient are diminished.... | 09/02/2003 |
| 6602851 | SMDF and GGF neuregulin splice variant isoforms and uses thereof Distinct cDNAs encoding six cysteine-rich domain-NRGs and four glial growth factor isoforms were identified and sequenced. Additional heterogeneity is found in the EGF-like (- and ଲ-isoforms) and carboxy terminal (a and b variant) regions of ... | 08/05/2003 |
| 6596687 | Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of us... | 07/22/2003 |
| 6593359 | Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis The use of at least one γ-RAR receptor-specific agonist ligand to prepare a pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating γ-RAR receptors is disclosed. The... | 07/15/2003 |
| 6589986 | Methods of treating anxiety disorders This invention provides methods for treating, preventing or inhibiting anxiety, anxiety-related conditions and phobias in a mammal using compounds of the formula: ##STR1## wherein: R1 is H, alkyl, alkanoyl or the radical Ar; R2 is H ... | 07/08/2003 |
| 6573236 | Inhibiting MOG-antibody binding The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoa... | 06/03/2003 |
| 6548500 | Reverse-turn mimetics and methods relating thereto Conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetics have utility in the treatment of cell adhesion-indicated diseases, su... | 04/15/2003 |
| 6531133 | Pseudomonas exotoxin-myelin basic protein chimeric proteins A chimeric protein comprising a Pseudomonas aeruginosa exotoxin (PE) moiety linked to a myelin basic protein (MBP) moiety is disclosed. The MBP moiety is selected from the group comprising: (a) MBP; (b) amino acids 69-88 of guinea-pig myelin basic protein... | 03/11/2003 |
| 6531493 | 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis The invention relates to the novel use of 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide , a pharmacologically tolerable salt thereof or its N-oxide in the treatment of multiple sclerosis.... | 03/11/2003 |
| 6518302 | Remedies ##STR1## Compounds represented by general formula (I) wherein X represents OH or OSO3 H; and R represents a substituent other than OH which allows, after leaving, the induction of unsaturated bonds into the 3- and 4-positions of 3,6-anhydrogala... | 02/11/2003 |
| 6506796 | Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis Methods of cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of 6-3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthan... | 01/14/2003 |
| 6488164 | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue Modafinil is effective in improving symptoms of attention deficit hyperactivity disorder and symptoms of multiple sclerosis fatigue. The administration of modafinil is also shown to activate the tuberomamillary neurons of the posterior hypothalamus, and t... | 12/03/2002 |
| 6455553 | Method for treating a demyelinating condition The present invention provides a method for treating a demyelinating condition in a subject in need of treatment, by administering to the subject an amount of a Ca2+ -channel blocker effective to treat the demyelinating condition. The present i... | 09/24/2002 |
| 6413968 | Treatment of myasthenia gravis by cyclic nucleotide phosphodiesterase inhibition A method of treating myasthenia gravis confined to the eyes iby administering, orally, a therapeutically effective dose the nucleotide (cGMP) phosphodiesterase inhibitor Sildenafil either 100 mg. once a day, or 25 mg. four times a day. The object of this ... | 07/02/2002 |
| 6362161 | Copolymer-1 improvements on compositions of copolymers The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.... | 03/26/2002 |
| 6342476 | Copolymer-1 improvements in compositions of copolymers The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.... | 01/29/2002 |
